Dr. Samantha Pulliam describes the leva Pelvic Health System

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.

Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.